ライフサイエンスコーパス: high-dose group

1 medium-dose group), or 25 mg BID carvedilol (high-dose group).

2 six in the medium-dose group, and 14 in the high-dose group).

3 ] in the low-dose group, and 20 [34%] in the high-dose group).

4 (93 in the standard-dose group and 97 in the high-dose group).

5 ts (217 in the low-dose group and 217 in the high-dose group).

6 p) or three 50 mg indometacin suppositories (high-dose group).

7 a slight increase in minor infections in the high dose group.

8 hology are observed most consistently in the high dose group.

9 jection and neurotoxicity were lowest in the high dose group.

10 IgG with the highest levels observed in the high-dose group.

11 ups, and 0.4 in the phenethyl isothiocyanate high-dose group.

12 the medium-dose group, and 59 percent in the high-dose group.

13 had a trend toward better improvement in the high-dose group.

14 agonist adverse effects were observed in the high-dose group.

15 ) to the low-dose group, and 58 (34%) to the high-dose group.

16 , and homocysteine tended to decrease in the high-dose group.

17 during cognitive testing was improved in the high-dose group.

18 group, and 5.0 x 10(10) viral particles in a high-dose group.

19 ow-dose group and 4.0 (1.0-7.0) days for the high-dose group.

20 -dose group, and 4.8 IU per deciliter in the high-dose group.

21 during cognitive testing at endpoint in the high-dose group.

22 curred transiently in one participant in the high-dose group.

23 up, and 18.0 IU/mL (6.0-486.0 IU/mL) for the high-dose group.

24 SD] age, 70.7 [7.6]; 19 male [86.4%]) in the high-dose group.

25 d in the low-dose group versus 7 SAEs in the high-dose group.

26 area under the curve (AUC) of 0.942 for the high-dose group.

27 ime, and it may have improved dyspnea in the high-dose group.

28 ept for more early steroid withdrawal in the high-dose group.

29 .95% in the low-dose group and 33.62% in the high-dose group.

30 the medium-dose group, and 90% (n=10) in the high-dose group.

31 0.18% in the low-dose group and 52.6% in the high-dose group.

32 low- and mid-dose groups, and lowest in the high-dose group.

33 low-dose group, and 17 (8%) patients in the high-dose group.

34 group and 13 (33%) of 39 participants in the high-dose group.

35 was significantly delayed (P < 0.05) in the high-dose group.

36 ) and greater, but not significantly, in the high-dose group.

37 5% confidence interval: 0.65 to 0.79) in the high-dose group.

38 v-specific CD8 T cells were seen only in the high-dose group.

39 rmediate-dose group, and five of five in the high-dose group.

40 g intervals resulted in higher titers in the high dose groups.

41 nd exercise capacity occurred in medium- and high-dose groups.

42 ow-dose and 0.54 (95% CI: 0.46-0.63) for the high-dose groups.

43 rence -1.37 [95% CI -2.932 to 0.190]) or the high-dose group (-1.40 [-2.957 to 0.152]; p=0.0765).

44 or 1 were also higher in vixarelimab groups (high-dose group, 18 [38.3%]; mid-dose group, 14 [29.8%];

45 the medium-dose group (11.25x10(11)) or the high-dose group (19.63x10(11)) (P=0.002 for low vs. medi

46 of host inflammatory and hemostatic systems (high-dose group, 2.0 microg/kg; n = 5) to renal failure

47 For the high dose group, 20 of 64 base substitutions occurred at

48 180 to 25.5 mug/mL (95% CI 20.6-31.5) in the high-dose group, 22.1 mug/mL (19.3-28.6) in the low-dose

49 was significantly lower in the short-course, high-dose group (24%) compared with the standard-course

50 (2) (mean+/-SE) increased at 6 months in the high-dose group (24.0+/-4.2 mm Hg, 95% CI 15.5 to 32.4 m

51 nt, reported in 25 (62%) participants in the high-dose group, 25 (60%) participants in the low-dose g

52 ive response of splenocytes from rats in the high dose group (250 microg) to alpha3(IV)NC1 in vitro.

53 patients with a serological response in the high-dose group, 29 of 36 (80.6%) had anti-HBs titers gr

54 events in 30 (75%) of 40 participants in the high-dose group, 33 (79%) of 42 participants in the low-

55 the majority of bradycardia occurring in the high-dose group (37.5%).

56 om/s, p < 0.05), was higher in the CHF/ET(A) High Dose group (39+/-1 microm/s, p < 0.05), and was sim

57 ay 28 at 51 mug/mL (95% CI 41.1-63.3) in the high-dose group, 44.9 mug/mL (25.8-56.3) in the low-dose

58 a medium-dose group (2.5 x 10(1)0 vp), and a high-dose group (5 x 10(1)0 vp).

59 In the high-dose groups (560 and 980 mg dose groups), a respons

60 on (55 to the standard-dose group, 52 to the high-dose group); 81 (75.7%) were men, and the mean (SD)

61 to treatment was higher in the short-course, high-dose group (82% vs 74%; P =.02).

62 zation (loss of less than 15 letters) in the high-dose group (96.3%) compared with low-dose (83.3%) a

63 a 50-mg maintenance dose every 12 hours (the high-dose group); a 60-mg loading dose of VX-548, follow

64 In the high-dose group, a consistent increase in the factor IX

65 Reductions in insulin AUC were larger in the high-dose group (adjusted mean difference, -3.56 [95% CI

66 tal admissions was 0.0937 (SD 0.3644) in the high-dose group and 0.1017 (0.3708) in the standard-dose

67 r child was 1.05 (95% CI, 0.91-1.19) for the high-dose group and 1.03 (95% CI, 0.90-1.16) for the sta

68 ipants (Kaplan-Meier estimate, 44.6%) in the high-dose group and 100 participants (Kaplan-Meier estim

69 nderwent randomization (1093 patients to the high-dose group and 1048 to the low-dose group).

70 Nineteen (33%) of 57 patients in the high-dose group and 11 (20%) of 54 patients in the moder

71 er injection in 12 (30%) participants in the high-dose group and 11 (26%) participants in the low-dos

72 nti-HB levels were 398.0 (433.4) IU/L in the high-dose group and 158.5 (301.4) IU/L in the standard-d

73 s of an event within 2 years of 18.0% in the high-dose group and 18.6% in the low-dose group.

74 3 days (interquartile range, 4 to 39) in the high-dose group and 24 days (interquartile range, 6 to 5

75 eat population (249 randomly assigned to the high-dose group and 250 to the standard-dose group), of

76 48.7 ng/mL (95% CI, 46.9-50.5 ng/mL) in the high-dose group and 36.8 ng/mL (95% CI, 35.4-38.2 ng/mL)

77 iesis-stimulating agent was 29,757 IU in the high-dose group and 38,805 IU in the low-dose group (med

78 vents approach, there were 429 events in the high-dose group and 507 in the low-dose group (rate rati

79 dropped 4.8+/-10.3 (mean+/-SD) units in the high-dose group and 6.9+/-8.4 units in the low-dose grou

80 ction was 79.3% (SE 4.0) for patients in the high-dose group and 75.5% (4.2) for the low-dose group.

81 Ebola virus in 14 (100%) participants in the high-dose group and elicited seropositivity to Sudan vir

82 occurred in 0.06% of the participants in the high-dose group and in 0.11% of those in the standard-do

83 occurred in 1138 participants (0.68%) in the high-dose group and in 1210 (0.73%) in the standard-dose

84 3 participants (absolute risk, 0.26%) in the high-dose group and in 227 of 66,789 (absolute risk, 0.3

85 occurred in 8.0% of the participants in the high-dose group and in 4.4% of those in the standard-dos

86 3 participants (absolute risk, 0.09%) in the high-dose group and in 92 of 66,789 (absolute risk, 0.14

87 mpare the incidence of MRD positivity of the high-dose group and the low-dose group at day 22 of indu

88 organisms robustly colonized the gut in the high-dose group and were among the top taxa associated w

89 ne to the intermediate-dose, and nine to the high-dose group) and received a dose; 23 were available

90 sed by 120%, was normalized in the CHF/ET(A) High Dose group, and fell by 43% from CHF values in the

91 patients in the medium-dose group, 3 in the high-dose group, and 1 in the placebo group discontinued

92 low-dose group, 4 of 88 infants (5%) in the high-dose group, and 10 of 97 infants (10%) in the place

93 e in the low-dose group, 70% of those in the high-dose group, and 100% of those in the placebo group

94 urred in 28 in the low-dose group, 19 in the high-dose group, and 29 in the placebo group.

95 urred in 32 in the low-dose group, 28 in the high-dose group, and 38 in the placebo group.

96 se group, 47 (82%) of 57 participants in the high-dose group, and 43 (73%) of 59 participants in the

97 en in the low-dose group, 54 children in the high-dose group, and 54 in the placebo group).

98 dose group, 17 of 52 patients (32.7%) in the high-dose group, and 9 of 58 patients (15.5%) in the pla

99 in the low-dose group, 100% of those in the high-dose group, and 92% of those in the placebo group h

100 group, seven (12%) of 57 participants in the high-dose group, and seven (12%) of 59 participants in t

101 Sudan virus in 12 (86%) participants in the high-dose group; antibody titres were boosted in the two

102 e than 30% in 2008 and by 24% in 2009 in the high-dose group as compared with that in the placebo gro

103 ssignment: the relative risk of death in the high-dose group as compared with the standard-dose group

104 7 and week 10 in 4 of the 6 patients in the high-dose group but resolved over a median of 5 days (ra

105 ficiency was observed more frequently in the high-dose group, but the 2 groups were similar in the nu

106 oup and a nonsignificantly lower risk in the high-dose group by 2% for stroke, 7% for CHD events, and

107 roup B), or 7.2 mg of DNA administered i.m. (high-dose group C) each time.

108 d necrosis were significantly reduced in the high dose group compared with the control group.

109 nses was elevated in PBMCs isolated from the high dose group compared with the low dose group.

110 , urinary FB1 was significantly decreased in high-dose group compared to that of placebo group (p = 0

111 There was a 0.8 mean letter gain in the high-dose group compared with a 9.7 mean letter loss in

112 fforded a significant stronger effect in the high-dose group compared with low-dose propofol.

113 evels of tissue-specific ACE activity in the high-dose group compared with the low-dose group at the

114 in outcome for either aptiganel (low-dose or high-dose) group compared with the placebo group at 90 d

115 Plasma from animals in the high-dose group completely inhibited platelet aggregatio

116 One patient was excluded from the high-dose group due to a diagnosis of progressive supran

117 tene significantly increased in the mid- and high dose groups during the trial.

118 ct that was significantly more common in the high-dose group during treatment.

119 In contrast, the high-dose group experienced a statistically significant

120 between control and moderate and control and high dose groups for constant pressure pain intensity (p

121 n rates after vaccination were higher in the high-dose group for the H1N1 (96% vs. 87%; treatment dif

122 no symptoms," as did 24 of 66 (36.4%) in the high-dose group, for a difference of -7.9% (95% CI, -24.

123 Moderate and high dose groups had the greatest reductions in ratings

124 red with the low-dose group, patients in the high-dose group had a nonsignificant 8% lower risk of de

125 A total of 320 patients (29.3%) in the high-dose group had a primary end-point event, as compar

126 The high-dose group had higher serum total folate (median: 1

127 ction was observed (both p = .02), such that high-dose group had less and longer time to relapses tha

128 s (80.0%) with a serological response in the high-dose group had protective anti-HBs vs 9 of 23 patie

129 The high-dose group had significantly fewer illicit opioid-p

130 The high-dose group had significantly greater decreases in i

131 The high-dose group had significantly lower mean white blood

132 eat analysis through week 30 patients in the high-dose group had significantly lower rates of opioid-

133 The high-dose group had significantly lower self-reported he

134 Most patients (57%) were in the high-dose group; here, 80% of these patients had a basel

135 There were more clinic attendances by the high-dose group in the first 6 months of life (p=0.018).

136 ognized by postvaccination sera from the two high-dose groups, including large segments spanning the

137 ; 12 months: P=0.054), with the low-dose and high-dose groups individually showing trends toward impr

138 segments and in 1313 of 1360 segments in the high-dose group (kappa = 0.73), in 1321 of 1354 and in 1

139 better revealed that 100% of patients in the high-dose group lost <15 letters compared with 55.6% in

140 between dose groups in treatment retention (high-dose group mean retention, 159 days; moderate-dose

141 tients' global assessment of symptoms in the high-dose group (mean AUC, 4430+/-1401 vs. 4171+/-1436;

142 edian [IQR] birth weight, 1200 [976-1425] g; high-dose group: median [IQR] GA, 29.0 [27.7-30.5] weeks

143 were randomly allocated into 5 groups: BSJYD high dose group, middle dose group, low dose group, capt

144 pants were included (low-dose group, n = 10; high-dose group, n = 10; control group, n = 9).

145 activity and serum aldosterone levels in the high-dose group, no statistically significant difference

146 the low-dose group versus 63 (64%) from the high-dose group (odds ratio [OR] 2.1; 95% CI, 1.1-3.7; p

147 dative stress parameters in both the low and high dose groups of DME-treated arthritic animals.

148 in the low-dose group and 145.9 EU/ml in the high-dose group on day 42).

149 alysis, three of 65 participants (5%) in the high-dose group, one of 34 (3%) participants in the low-

150 ) in the low-dose group, and two (3%) in the high-dose group; only one (an acute allergic skin reacti

151 for a cumulative dose of 35 mg per kilogram; high-dose group) or matched placebo (standard-dose group

152 (low dose group), 500 U/kg of human AT-III (high dose group), or normal saline (control group) on da

153 f rVSVDeltaG-ZEBOV-GP (1 x 108 pfu, n = 264; high-dose group), or placebo (n = 133).

154 se group, and 17 (8%) of 211 patients in the high-dose group, or diarrhoea, reported by seven (3%) pa

155 oth dose groups versus in the placebo group (high-dose group P = .047).

156 D]) to 12 weeks (391.1 +/- 153.0 min) in the high dose group (p < 0.01).

157 eeks for lag phase for the placebo, mid- and high dose groups (p = 0.004 for trend).

158 P < 0.001) and a 37% higher mortality in the high-dose group (P < 0.001).

159 ared with 26.9% (95% CI, 18.3%-37.8%) in the high-dose group (P = .03).

160 placebo, 22% in the low-dose, and 17% in the high-dose group (p = .26 for placebo vs. high dose).

161 statin group (p trend <0.001) but not in the high-dose group (p = 0.03 for test for interaction of BM

162 versus placebo), 18 patients (34.6%) in the high-dose group (P = 0.103 versus placebo), and 29 patie

163 low-dose group and 0.10 mg/dl per yr in the high-dose group (P: = 0.51).

164 ESRD: 10 in the low-dose group and 8 in the high-dose group (P: = 0.56).

165 asone group compared with 87% (82-92) in the high-dose group (p=0.0002).

166 21% in the low-dose group versus 33% in the high-dose group (P=0.007) and 23% in the thyrotropin alf

167 he mean (+/-SE) scores were 2.8+/-0.1 in the high-dose group (P=0.008) and 2.8+/-0.1 in the low-dose

168 , the mean scores were 2.7+/-0.1 in both the high-dose group (P=0.048) and the low-dose group (P=0.14

169 ally significant difference between low- and high-dose groups (P = .84).

170 ompared to placebo, which was significant in high-dose groups (P = 0.008 and P < 0.001, respectively)

171 ts in the low-dose, and four patients in the high-dose groups (p = 0.12); 30-day myocardial infarctio

172 s. three in the medium-dose and three in the high-dose group; P<0.001 for low vs. medium and low vs.

173 Patients in the high-dose group received a median monthly iron dose of 2

174 ocol was amended so that a subgroup from the high-dose group received a second high dose of vaccine 1

175 fter the procedure, patients assigned to the high-dose group received an additional 50 mg indometacin

176 Seven participants in the high-dose group received one vaccine dose and seven rece

177 However, a high-dose group receiving 112.5mg/kg DE showed a conside

178 n 90% reduction in illicit opioid use by the high-dose group relative to pretreatment levels.

179 w-dose group, the medium-dose group, and the high-dose group, respectively (differences were not sign

180 10 or 30 mg per kilogram (low-dose group and high-dose group, respectively) or placebo, for 10 infusi

181 d 2 h (7.70 +/- 6.8 mumol/L) in the low- and high-dose groups, respectively (P < 0.05).

182 75%, and 4.24% in the placebo, low-dose, and high-dose groups, respectively (P =.032 for the high-dos

183 A at baseline (94% and 97% for the low- and high-dose groups, respectively) but for only 22% and 14%

184 nd 10 patients in the placebo, low-dose, and high-dose groups, respectively, completed at least 4 wee

185 and 7 patients in the placebo, low-dose, and high-dose groups, respectively, were enrolled in the ope

186 y 22% and 14% at peak times for the low- and high-dose groups, respectively.

187 mol (P < 0.001) vs. saline for both low- and high-dose groups, respectively.

188 tion in serum T4, in the dams of the low and high-dose groups, respectively.

189 .6, and 2.1 hours for the low-, medium-, and high-dose groups, respectively; P=0.028).

190 1.3; P=0.5) and 23.0 percent of those in the high-dose group (risk ratio, 1.2; 95 percent confidence

191 tibility was also lower in the short-course, high-dose group (RR, 0.77; 95% CI, 0.58-1.03; P =.08).

192 .04; 95% CI, 1.50 to 2.76; P < 0.0001 in the high-dose group; RR relative to the middle quintiles).

193 Middle and High dose groups showed significantly higher tumor %ID/g

194 ggested a 6.4% increase (P=0.069), while the high-dose group showed a 7.9% increase (P=0.040) over pl

195 % CI, 0.55-0.86; P = 0.001), the TA 10-mg/ml high-dose group showed similar odds (OR, 0.90; 95% CI, 0

196 P = 0.40), and the TA 40-mg/ml low-dose and high-dose groups showed higher odds of an event occurrin

197 e fovea (P < or = 039), with response in the high-dose group significantly different from that in the

198 ulmonary cavities developed in both low- and high-dose groups, some beginning as early as 6 weeks.

199 More patients in the high-dose group than in the low-dose group were hospital

200 homocysteine was 2 micromol/L greater in the high-dose group than in the low-dose group, but there wa

201 se with > or = 2 functions) were seen in the high-dose group than in the other groups.

202 beats/min) was more frequently noted in the high-dose group than in the standard-dose group (p < .05

203 ose group; all 23 [100%] participants in the high-dose group) than in the placebo group (6 [50%] of 1

204 he equilibrated Kt/V was 1.16+/-0.08; in the high-dose group, the values were 75.2+/-2.5 percent, 1.7

205 to P=.042) in the low-dose group than in the high-dose group; this finding was consistent with recept

206 Noninferiority of the high-dose group to the low-dose group would be establish

207 was diarrhea, which caused 1 patient in the high-dose group to withdraw from the trial.

208 th 31 nmol of 99mTc-labeled Cy7 tilmanocept (high-dose group) to saturate the receptor sites within t

209 median tissue culture infectious dose) or a high-dose group (two doses at 1 x 10(5) times the median

210 group = valganciclovir 450 mg/day [n = 130]; high-dose group = valganciclovir 900 mg/day [n = s7]) we

211 The high-dose group versus placebo met the prespecified crit

212 the 16-week DB period: vixarelimab, 540 mg (high-dose group); vixarelimab, 360 mg (mid-dose group);

213 95 months (95% CI, 3.02-5.95 months) for the high-dose group vs 3.29 months (95% CI, 2.66-4.14 months

214 k of HIV progression or death was 72% in the high-dose group vs 72% in the standard-dose group (risk

215 2000 IU/d of vitamin D oral supplementation (high-dose group) vs 354 participants who were randomized

216 The increase in WBPB for the high-dose group was 10.0+/-3.7, and that for the moderat

217 The median daily dose in the high-dose group was 9 MIU (interquartile range [IQR], 9-

218 arked incorporation of deuterated Met in the high-dose group was accompanied with a striking increase

219 Serological response in the high-dose group was found in 36 of 50 patients (72%; 95%

220 ity rate in the lowest eKt/V quintile of the high-dose group was higher than in the full standard-dos

221 us 11.0+/-1.2, P=0.035); measurements in the high-dose group were also lower, but not significantly.

222 ical characteristics between the control and high-dose group were similar for age (95% confidence int

223 41 patients in low-dose and 4330 patients in high-dose groups) were included.

224 TNF-alpha was reduced in the high-dose group, whereas gamma-aminobutyric acid (GABA)